AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02739477
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results.
Trial: NCT04095572
Drug: intravesical instillation of sterile purified water
RxNorm normalized name: WATER,PURIFIED
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
Trial: NCT04059406
Drug: sapablursen
RxNorm normalized name: Sapablursen
DrugBank: Sapablursen (DB18608)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapablursen administered subcutaneously
Trial: NCT00959933
Drug: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)
RxNorm normalized name: ribavirin 200 MG
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00959933
Drug: Rebetol 200 Capsules (Schering Corporation, U.S.A.)
RxNorm normalized name: S-adenosylmethionine 200 MG
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02002403
Drug: Danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03278015
Drug: Nab-paclitaxel plus Gemcitabine
RxNorm normalized name: Paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
Trial: NCT03278015
Drug: Gemcitabine monotherapy
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
Trial: NCT03716856
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine is used for lymphodepletion.
Trial: NCT03273296
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin (po) 500 mg x 3 per day for 3 days.
Trial: NCT03273296
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin (po) 125 mg x 4 per day for 3 days.
Trial: NCT00361140
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs.
Trial: NCT00361140
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
Trial: NCT03491644
Drug: Titrated Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Restrictive treatment with oxygen.
Trial: NCT03491644
Drug: Liberal Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal treatment with oxygen.
Trial: NCT03078270
Drug: botulinum toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
Trial: NCT02323971
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01354158
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
Trial: NCT02811861
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02811861
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02811861
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02811861
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02291887
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of Ranibizumab
Trial: NCT02291887
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection of Aflibercept
Trial: NCT00686166
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m\^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m\^2, IV, Days 50,57,71,78
Trial: NCT03506256
Drug: Norfloxacin 400 MG
RxNorm normalized name: norfloxacin 400 MG
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
Trial: NCT03150862
Drug: Pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT03150862
Drug: TMZ
RxNorm normalized name: TMZ
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as specified in the treatment arm
Trial: NCT06758167
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A commonly used drug in MDD treatment.
Trial: NCT01595685
Drug: Telbivudine
RxNorm normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telbivudine 600 mg Daily Oral
Trial: NCT01595685
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5 mg Daily Oral
Trial: NCT01258309
Drug: olopatadine hydrochloride 0.1% ophthalmic solution
RxNorm normalized name: Olopatadine Hydrochloride 0.1% Ophthalmic Solution
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
Trial: NCT04445025
Drug: Elagolix 200 MG
RxNorm normalized name: elagolix 200 MG
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 200mg twice daily orally for 60 days prior to beginning frozen embryo transfer preparation
Trial: NCT04445025
Drug: Leuprolide Acetate 3.75 MG/ML
RxNorm normalized name: leuprolide acetate 3.75 MG/ML
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide Acetate intramuscularly every 28 days (twice) prior to beginning frozen embryo transfer preparation
Trial: NCT03354598
Drug: Sulopenem-Etzadroxil/Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of uncomplicated urinary tract infection
Trial: NCT03354598
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of uncomplicated urinary tract infection
Trial: NCT00006464
Drug: 7-hydroxystaurosporine
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00006464
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00702988
Drug: Org 36286
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
Trial: NCT00456300
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
Trial: NCT00456300
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject received a baseline study with insulin alone
Trial: NCT01605513
Drug: interferon
RxNorm normalized name: Interferon
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
Trial: NCT00066248
Drug: cyproheptadine hydrochloride
RxNorm normalized name: Cyproheptadine Hydrochloride
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
Trial: NCT00066248
Drug: megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
Trial: NCT02025881
Drug: Carboplatin + etoposide
RxNorm normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 160 mg/m\^2 Day 1 to day 5, as an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m\^2 D ay 1 to day 5, as an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle.
Trial: NCT02025881
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa 200 mg/m² Day-3 to day-1, as an intravenously infusion over 1 hour dilution in 200 ml/m\^2 of 5% glucose saline or sodium chloride 9 mg/ml (0.9%).
Trial: NCT02025881
Drug: Temozolimide + Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: During 2 cycles of 21 days:~* Temozolomide: 100 mg/m\^2/day PO from Day 1 to Day 5;~* Irinotecan: 10 mg/m\^2/day IV from Day 1 to Day 5 + from Day 8 to Day 12
Trial: NCT02025881
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m\^2/day PO during 5 days, during 6 cycles of 21 days
Trial: NCT01147224
Drug: Alvesco
RxNorm normalized name: Alvesco
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is an observational study. Therefore, the physician decides about dosage according to individual needs.
Trial: NCT00209417
Drug: Iodixanol 320-Arm 1
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00209417
Drug: Iopamidol 300-Arm 2
RxNorm normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00108602
Drug: acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00181948
Drug: atomoxetine (Strattera)
RxNorm normalized name: atomoxetine Oral Capsule [Strattera]
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04049175
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet of CHF 6532
Trial: NCT04049175
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet of CHF 6532 placebo
Trial: NCT02658760
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine plus placebo
Trial: NCT02658760
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dexmedetomidine and Bupivacaine
Trial: NCT01512160
Drug: PF-04531083
RxNorm normalized name: Pf-04531083
DrugBank: Pf-04531083 (DB12468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg oral solution
Trial: NCT01512160
Drug: PF-04531083
RxNorm normalized name: Pf-04531083
DrugBank: Pf-04531083 (DB12468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg oral solution
Trial: NCT01756430
Drug: Carvedilol SR 32mg, QD
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Carvedilol SR 32mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
Trial: NCT01756430
Drug: Carvedilol SR 64mg, QD
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Carvedilol SR 64mg QD for 4 weeks~* With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks.
Trial: NCT01756430
Drug: Carvedilol IR 25mg, QD
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Carvedilol IR 25mg QD for 4 weeks~* With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks.
Trial: NCT01756430
Drug: Carvedilol IR 25mg, BID
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Carvedilol IR 25mg BID for 4 weeks~* With the others investigation product placebo 2 capsules QD for 4 weeks.
Trial: NCT02459938
Drug: Glucagon (ZP-Glucagon)
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
Trial: NCT02459938
Drug: Glucagon (GlucaGen)
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant glucagon administered via subcutaneous injection
Trial: NCT03740373
Drug: BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold
RxNorm normalized name: calcium chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath-hold.
Trial: NCT04222062
Drug: Carmustine 7.7Mg Wafer
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLIADEL wafers will be placed to cover tumor bed immediately after tumor removal.
Trial: NCT00556192
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~2. A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~3. Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period.
Trial: NCT02535273
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
Trial: NCT03740373
Drug: BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold
RxNorm normalized name: (S)-3-Isobutyl GABA
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath-hold.
Trial: NCT02535273
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
Trial: NCT02535273
Drug: Low-dose Dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
Trial: NCT03691727
Drug: tirofiban hydrochloride (AGGRASTAT®)
RxNorm normalized name: tirofiban Injection [Aggrastat]
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
Trial: NCT01108627
Drug: foradil
RxNorm normalized name: Foradil
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: open-labeled inhaled corticosteroids (ICS); foradil
Trial: NCT00494962
Drug: lecozotan SR
RxNorm normalized name: Lecozotan
DrugBank: Lecozotan (DB12540)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02732262
Drug: Oxycodone, 1.00 mg dose
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
Trial: NCT02732262
Drug: Oxycodone, 0.03 mg/kg dose
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
Trial: NCT02732262
Drug: Oxycodone, 0.02 mg/kg dose
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
Trial: NCT02535273
Drug: Moderate-dose Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
Trial: NCT02535273
Drug: High-dose Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
Trial: NCT02285374
Drug: Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
Trial: NCT00006760
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: V over 24 hours on days 1-4
Trial: NCT00006760
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV over 6-10 minutes on days 1 and 5.
Trial: NCT00468364
Drug: insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03927950
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: escitalopram 10-20mg per day 12 weeks
Trial: NCT03927950
Drug: bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bupropion 150-300mg per day 6 weeks
Trial: NCT03945188
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
Trial: NCT01515410
Drug: DM-1992
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 72.5mg carbidopa/230mg levodopa
Trial: NCT02219048
Drug: PF-03715455
RxNorm normalized name: PF-03715455
DrugBank: PF-03715455 (DB12138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
Trial: NCT04410198
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Trial: NCT01016210
Drug: Leuveris
RxNorm normalized name: Luveris
DrugBank: Lutropin alfa (DB00044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV